New York Markets After Hours

InSightec's uterine fibroid treatment OKd by FDA

HeatherWilson

SAN FRANCISCO (CBS.MW) -- InSightec said Friday that its ExAblate 2000 system has received pre-market approval from the U.S. Food and Drug Administration. The ExAblate 2000 is a non-invasive surgical device used to treat uterine fibroids. Elbit Medical Imaging Ltd.
EMITF, -3.12%
and General Electric
GE, -0.72%
are major shareholders in privately held InSightec.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information.
All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.
Intraday data delayed at least 15 minutes or per exchange requirements.